Companies / ACELYRIN, Inc.
ACELYRIN, Inc.
SLRNCIK 1962918
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| May 9, 2023 | Westlake BioPartners Fund II, L.P. 10% owner | Buy Open-market buy | Common Stock | $22.50M | +1.3M +14.64% | 9,790,729 | high |
| May 9, 2023 | Seidenberg Beth C Director | Buy Open-market buy | Common Stock | $22.50M | +1.3M +14.64% | 9,790,729 | high |
| May 9, 2023 | Lin Shao-Lee CEO | Other Withheld for taxes | Common Stock | $8.32M | -337K -30.45% | 770,034 | low |
| May 9, 2023 | Seidenberg Beth C Director | Buy Open-market buy | Common Stock | $1.08M | +60K | 60,000 | high |
| May 9, 2023 | Gosebruch Henry O Director | Buy Open-market buy | Common Stock | $900.0K | +50K | 50,000 | high |
| May 9, 2023 | Svoronos Dawn Director | Buy Open-market buy | Common Stock | $270.0K | +15K | 15,000 | medium |
| Feb 20, 2024 | Lin Shao-Lee CEO | Sell Open-market sale | Common Stock | $119.4K | -16K -0.98% | 1,587,335 | medium |
| May 9, 2023 | Peloso Paul Executive | Buy Open-market buy | Common Stock | $108.0K | +6K | 6,000 | medium |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| SLRN | common | 00445A100 |